Biocept to Present at Molecular Medicine Tri-Con 2016
"First generation CTC detection systems were designed to capture only cells expressing an antigen found on epithelial tumor cells, known as EpCAM. These approaches miss non-EpCAM expressing types of tumor cells, such as those with mesenchymal or stem cell properties, that can contain important tumor related information," said
"The proprietary platforms we have developed at
About the Molecular Medicine Tri-Con
The 23rd Annual Molecular Medicine Tri-Con conference is a diverse event, focusing on molecular medicine, specifically on discovery, genomics, diagnostics and information technology.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the potential of our diagnostic assays to improve the detection and treatment of cancer, the
growing level of interest in liquid biopsy, and our ability to introduce
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-molecular-medicine-tri-con-2016-300229654.html
SOURCE
News Provided by Acquire Media